Escalante LA

Language: Spanish
References: 50
Page: 106-114
PDF size: 163.67 Kb.

ABSTRACT

The human intestinal flora maintains a close relationship in equilibrium with the host’s health. It is possible to manipulate the composition of the intestinal flora by dietetic methods to ensure their associated benefits on human health. Dietary methods for achieve this objective have been developed. The first is the probiotic approach, which introduces to the human gut living bacteria that reach the small intestine and colon. As a consequence of the metabolic activity of these living bacteria, the host shows some beneficial effects such as assistance in lactose intolerance, reduction in duration of several types of diarrhea, immunopromoting effect and anticancer properties. The second approach is the use of prebiotics, which provides specific carbon sources for probiotics bacteria. Despite there are many scientific and clinic evidences that validates their use, we also need to know the specific mechanisms behind these benefits associated with the manipulation of intestinal flora. The present paper shows an overview of the probiotics and prebiotic strategies for the management of intestinal flora.

REFERENCES

1. Ballongue J. Bifidobacteria and probiotic action. USA. Salminen S, von Wright A (Ed.), 1993:357-428.

2. Mitsuoka T. Intestinal bacteria and health. An introductory narrative. Japan. Harcourt Brave Javanovich, 1987:179-94.

3. Mitsuoka T. History and future prospects of intestinal flora research. Japan: Special Anniversary Edition of Healthist, 1997:13-17.

4. Mitsuoka T. The intestinal flora and its important relationship with health. Japan: Special Anniversary Edition of Healthist, 1997:2-12.

5. Tannock GW. A freshlook of the intestinal microflora. England: Tannock GW, 1999:5-14.

6. Mikelsaar M, Mändar R. Development of individual lactic acid microflora on the human microbial ecology. USA: Salminen S, von Wright A, 1993:273-93.

7. Itoh K. Colonization and control of intestinal flora. Japan: Special Anniversary Edition of Healthist, 1997: 18-24.

8. O’Sullivan DJ. Methods of analysis of the intestinal microflora. England: Tannock GW, 1999:23-44.

9. Ratcliffe B, McMillan J. The potential for benefical manipulation of the gut microflora by dietary means. BNF Nut Bull 1999;24:82-89.

10. Klaenhammer TR, Kullen MJ. Selection and design of probiotics. Int J Food Microbiol 1999;50:45-57.

11. Salminen S, Ouwehand A, Benno A, Lee YK. Probiotics: how should they be defined? Trends Food Sci Tech 1999;10:107-10.

12. Gibson GR, Fuller R. Prebiotics and probiotics: Microbes on the menu. Carbohydrates 1998;9:1-3.

13. Gibson GR. Dietary modulation of the human gut microflora using probiotics. Br J Nutr 1998;80:S209-12.

14. Famularo G, De Simone C, Mateeuzzi D, Pirovano F. Traditional and high potency probiotic for oral bacteriotherapy. BioDrugs 1999;12:455-470.

15. Svensson U. Industrial perspectives. England: Tannock GW, 1999:57-64.

16. Haesman M, Melletin J. Probiotic power. Dairy Ind Int 1999:19-20.

17. Longman B. Growth of prebiotic and probiotics dairy products opens new niches. Food Ingred 1999:33-36.

18. Lilly DN, Stiwell RH. Probiotics: growth promoting factors produced by microorganisms. Science 1965;147:747-48.

19. Parker RB. Probiotics: The other half of the antibiotic story. An Nut Health 1974;29:4-8.

20. Fuller R. Probiotics in man and animals. J. Appl Bacteriol 1989;66:365-378.

21. Tannock GW. Identification of lactobacilli and bifidobacteria. England: Tannock GW, 1999:45-56.

22. Pol J. Improved mineral absorption. Prebiotic opportunities. Int Food Technol 1999:9-11.

23. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of probiotics. Br J Nutr 1995;125:1401-12.

24. Ballongue J, Schumann C, Quignon P. Effects of lactulose an lactinol on colonic microflora and enzymatic activity. Scand J Gastroenterol 1997;Suppl222:41-44.

25. Terada A, Hara H, Katoaka M, Matsuoka T. Effect of lactulose on the composition and metabolic activity of the human fecal flora. Microb Ecol Health Dis 1992;5:43-50.

26. Crittenden RG. Prebiotics. England: Tannock GW, 1999:141-56.

27. Rowland IR, Tanaka R. The effects of transgalactosylated oligosaccharides on gut flora metabolisms associated with human fecal microflora. J Appl Bacteriol 1993;74:667-74.

28. Bouhnik YB, Flourié L, D’Agay-Abemsour D, Pochart P, Gramet G, Durand M, Rambaud JC. Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. J Nutr 1997;127:444-48.

29. Ito M, Degunchi Y, Miyamori A, Matsumoto A, Kikuchi H, Matsumoto K, Kobayashi Y, Yakiama T, Kan T. Effects of administration of galactooligosaccharides on the human fecal microflora, stool weight and abdominal sensation. Microb Ecol Health Dis 1999;3:285-92.

30. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 1995;108:975-982.

31. Roberfroid MB, Van Loo JAE, Gibson GR. The bifidogenic nature of chicory inulin and its hydrolysis products. J Nutr 1998;128:11-19.

32. Hayakawa K, Mizutani J, Wada K, Masai T, Yoshihara I, Mitsuoka T. Effect of soybean oligosaccharides on human fecal microflora. Microb Health Dis 1990;3:322-31.

33. Benno Y, Endo K, Shiragami N, Sayama K, Mitsuoka T. Effects of raffinose intake in human fecal microflora. Bifid Microfl 1987;6:59-63.

34. Kleesen B, Sykura B, Zuntf HJ, Blaut JM. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clinic Nutr 1997;65:1397-402.

35. Salminen S, Isoulari E, Salminen E. Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. England: Venema G, Huis in’t Veld JHJ, Hugenholtz J. 1996:347-58.

36. Atlas RM. Probiotics -snake oil for the new millennium. Environ Microbiol 1999;1:375-82.

37. Guandalini S, Pensabene L, Zikri MA et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Ped Gastroenterol Nut 2000;30:54-60.

38. Ross SNH, Katan MB. Effects of probiotics bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000;71:405-11.

39. Tanaka R. Lactobacillus, bifidobacterium and intestinal infections diarrhea. Japan: Special Anniversary Edition of Healthist, 1997:121-28.

40. Oikawa T. Intestinal infections during early childhood (including intractable diarrhea). Japan: Special Anniversary Edition of Healthist, 1997:110-28.

41. Rowland I. Probiotics and benefits to human health -the evidence in favor. Environ Microbiol 1999;1:375-382.

42. Isoulari E. The use of probiotics in pediatrics. Hosp Med 2000;61:6-7.

43. Davidson PM, Hoover DG. Antimicrobial components from lactic acid bacteria. USA: Salminen S, von Wright A, 1993:127-159.

44. Morotomi M. Intestinal bacteria and cancer. Japan: Special Anniversary Edition of Healthist, 1997:35-44.

45. McCraken VJ, Gaskins HR. Probiotics and the immune system. England: Tannock GW, 1997:85-111.

46. Kato I. Immunopotentiating action of Lactobacillus. Japan: Special Anniversary Edition of Healthist. 1997:60-66.

47. Ishikawa H. Immune tolerance in the intestines. Japan: Special Anniversary Edition of Healthist. 1997:789-87.

48. Kirjavainen PV, Apostolou E, Salininen SJ, Isoulari E. New aspects of probiotics -a novel approach in the management of food allergy. Allergy 1997;54:909-15.

49. Kaminokawa S. Allergies and the intestinal environment. Japan: Special Anniversary Edition of Healthist, 1997:121-28.

50. Tanaka R. The effect of the ingestion of fermented milk with Lactobacillus casei Shirota on the gastrointestinal microbial ecology in healthy volunteers. United Kingdom: Leeds AR, Rowland IR, 1996:37-45.